Gene · 6607
Papers3,510
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,341 to 1,360 of 3,510
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy. | Ther Adv Neurol Disord | 2021 | 33747131 | PubTator, text mining | PubMed |
| Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. | Lancet Neurol | 2021 | 33743238 | PubTator, text mining | PubMed |
| Gene therapy for spinal muscular atrophy: hope and caution. | Lancet Neurol | 2021 | 33743228 | PubTator, text mining | PubMed |
| Beyond copy number: A new, rapid, and versatile method for sequencing the entire SMN2 gene in SMA patients. | Hum Mutat | 2021 | 33739559 | PubTator, text mining | PubMed |
| Modular Synthesis of Trifunctional Peptide-oligonucleotide Conjugates via Native Chemical Ligation. | Front Chem | 2021 | 33738276 | PubTator, text mining | PubMed |
| A high-throughput screening to identify small molecules that suppress huntingtin promoter activity or activate huntingtin-antisense promoter activity. | Sci Rep | 2021 | 33731741 | PubTator, text mining | PubMed |
| Integration of whole genome sequencing into a healthcare setting: high diagnostic rates across multiple clinical entities in 3219 rare disease patients. | Genome Med | 2021 | 33726816 | PubTator, text mining | PubMed |
An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER). | J Mark Access Health Policy | 2021 | 33708361 | PubTator, text mining | PubMed |
| A synthetic small molecule stalls pre-mRNA splicing by promoting an early-stage U2AF2-RNA complex. | Cell Chem Biol | 2021 | 33689684 | PubTator, text mining | PubMed |
| The altered expression of neurofilament in mouse models and patients with spinal muscular atrophy. | Ann Clin Transl Neurol | 2021 | 33683023 | PubTator, text mining | PubMed |
| Effect of Discontinuation of Nusinersen Treatment in Long-Standing SMA3. | J Neuromuscul Dis | 2021 | 33682724 | PubTator, text mining | PubMed |
| An in vitro reconstituted U1 snRNP allows the study of the disordered regions of the particle and the interactions with proteins and ligands. | Nucleic Acids Res | 2021 | 33677607 | PubTator, text mining | PubMed |
| Crosstalk between Different DNA Repair Pathways Contributes to Neurodegenerative Diseases. | Biology (Basel) | 2021 | 33669593 | PubTator, text mining | PubMed |
| Genes Regulating Spermatogenesis and Sperm Function Associated With Rare Disorders. | Front Cell Dev Biol | 2021 | 33665191 | PubTator, text mining | PubMed |
| Is cerebrospinal fluid amyloid-β42 a promising biomarker of response to nusinersen in adult spinal muscular atrophy patients? | Muscle Nerve | 2021 | 33660868 | PubTator, text mining | PubMed |
| Revisiting DCE-MRI: Classification of Prostate Tissue Using Descriptive Signal Enhancement Features Derived From DCE-MRI Acquisition With High Spatiotemporal Resolution. | Invest Radiol | 2021 | 33660631 | PubTator, text mining | PubMed |
| FBW7 suppresses ovarian cancer development by targeting the N6-methyladenosine binding protein YTHDF2. | Mol Cancer | 2021 | 33658012 | PubTator, text mining | PubMed |
| Cerebrospinal Fluid Parameters in Antisense Oligonucleotide-Treated Adult 5q-Spinal Muscular Atrophy Patients. | Brain Sci | 2021 | 33652830 | PubTator, text mining | PubMed |
| Bcl2l10 induces metabolic alterations in ovarian cancer cells by regulating the TCA cycle enzymes SDHD and IDH1. | Oncol Rep | 2021 | 33649794 | PubTator, text mining | PubMed |
| Emerging concepts underlying selective neuromuscular dysfunction in infantile-onset spinal muscular atrophy. | Neural Regen Res | 2021 | 33642371 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6607/papers?page=68